BioSpace News Archive

Genetown

La Jolla Pharmaceutical Company Announces Share Repurchase Plan - Nov 17, 2021

La Jolla Pharmaceutical Company announced that it will commence a share repurchase plan for up to $10 million of the Company’s common stock.

November 17, 2021
·
1 min read
Drug Development

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

Graphite Bio, Inc. today announced that the first patient has been enrolled in the company’s Phase 1/2 clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).

November 17, 2021
·
6 min read
Biotech Beach

Boundless Bio to Present at the Piper Sandler 33rd Annual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference

Boundless Bio to Present at the Piper Sandler 33rd Annual Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference.

November 17, 2021
·
1 min read
Business

Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors

Abintus Bio, Inc. today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.

November 17, 2021
·
4 min read
BioMidwest

DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

November 17, 2021
·
1 min read
Business

Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 4:30 PM EDT by Webcast and Conference Call

Anavex Life Sciences Corp. today announced that it will issue financial results for its fiscal year ended September 30, 2021 on Wednesday November 24, 2021 at 4:30 PM EDT.

November 17, 2021
·
3 min read
Pharm Country

NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven”) announced today that NURTEC® ODT (rimegepant) was approved by the Kuwait Ministry of Health for the acute treatment of migraine with and without aura in adults.

November 17, 2021
·
7 min read
Business

Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies

Castle Biosciences, Inc. today announced that it has been named in Inc.’s first-annual Best-Led Companies list, a select, data-driven list of the very strongest U.S. firms with revenue of $50 million to $2 billion.

November 17, 2021
·
5 min read
Policy

Update on Regulatory Review of Aducanumab in the European Union

Biogen Inc. and Eisai Co., Ltd. announced an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimer’s disease by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

November 17, 2021
·
8 min read
Business

Evogene Reports Third Quarter 2021 Financial Results

Conference call and webcast today, November 17, 2021, 9:00 am ET to provide its financial results.

November 17, 2021
·
16 min read